SCM
CALA

Segantii Capital Management’s Calithera Biosciences, Inc CALA Stock Holding History

Segantii Capital Management’s Portfolio CALA Stock Details CALA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-1,402
Closed -$324K – 308
2017
Q1 		$324K Buy
+1,402
New +$242K 0.05% 98

Other funds holding CALA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Segantii Capital Management's CALA Position: Q2 2017 in Review

Segantii Capital Management sold out of Calithera Biosciences, Inc (CALA) in Q2 2017, closing a stake of 1,402 shares — an estimated $324K sold.

Segantii Capital Management first reported a position in CALA in Q1 2017 and held it in 1 quarter. The position peaked at $324K in Q1 2017. 94 funds tracked by Wall St. Rank hold CALA as of Q2 2017.

  • Segantii Capital Management reported no remaining Calithera Biosciences, Inc position as of Q2 2017 after selling out during the quarter.
  • Segantii Capital Management sold 1,402 Calithera Biosciences, Inc shares in Q2 2017, an estimated $324K.
  • Segantii Capital Management first reported a position in Calithera Biosciences, Inc in Q1 2017 and held it in 1 quarter.
  • Segantii Capital Management's Calithera Biosciences, Inc position peaked at $324K in Q1 2017.
  • 94 funds tracked by Wall St. Rank held Calithera Biosciences, Inc as of Q2 2017.

Based on Segantii Capital Management's 13F filing for Q2 2017, filed 2 Aug 2017.